Lokelma Dosing for Potassium 5.2 mmol/L
For a potassium of 5.2 mmol/L, start Lokelma 10 g three times daily for up to 48 hours, then transition to 10 g once daily for maintenance. 1
Initial Treatment Phase (First 48 Hours)
- Administer 10 g three times daily (total 30 g/day) for up to 48 hours to rapidly normalize potassium levels 1
- This dosing achieves normalization (3.5-5.0 mmol/L) in a median of 2.2 hours, with 84% of patients reaching normal range within 24 hours 2
- The 10 g TID regimen produces a mean potassium reduction of approximately 1.1 mmol/L over 48 hours 3
- Mix each dose in approximately 3 tablespoons of water, stir well, and drink immediately 1
Maintenance Phase (After 48 Hours)
- Transition to 10 g once daily after achieving normalization 1
- Monitor serum potassium and adjust dose based on levels and target range 1
- The maintenance dose range is 5 g every other day to 15 g daily, adjusted in 5 g increments at weekly intervals or longer 1
- In clinical trials, 10 g once daily maintained mean potassium at 4.5 mmol/L over 28 days, with 90% of patients maintaining levels <5.1 mmol/L 3
Dosing Rationale for K+ 5.2 mmol/L
Your patient's potassium of 5.2 mmol/L falls into the mild hyperkalemia range (5.1-5.5 mmol/L) but still warrants the standard initial dosing regimen. The FDA-approved dosing does not stratify initial treatment by severity for non-dialysis patients—all receive 10 g TID initially 1. This approach is supported by phase 3 trials showing that 10 g TID effectively corrects hyperkalemia across the spectrum from 5.0-6.5 mmol/L 3, 4.
Important Medication Timing
- Separate other oral medications by at least 2 hours before or after Lokelma to avoid binding interactions 1
- This is particularly critical for medications with narrow therapeutic windows 3
Monitoring and Adjustment
- Recheck potassium within 24-48 hours during the initial phase 1
- Once on maintenance therapy, monitor at weekly intervals initially, then adjust frequency based on stability 1
- If potassium drops below target range, decrease dose by 5 g or discontinue 1
- Long-term data shows 88% of patients maintain potassium ≤5.1 mmol/L over 12 months with individualized dosing (mean dose 7.2 g daily) 5
Key Safety Considerations
- Each 5 g dose contains approximately 400 mg sodium—monitor for edema, especially in heart failure or fluid-sensitive patients 1
- Edema is generally mild-to-moderate and more common at the 15 g daily dose 1, 2
- Hypokalemia risk is low but increases with higher doses (10% at 10 g daily, 11% at 15 g daily in trials) 2
- Avoid in severe constipation or bowel obstruction as it has not been studied in these conditions 1
Context for Chronic Management
The 2025 European Heart Journal guidelines emphasize that potassium binders like Lokelma enable continuation of life-saving RAAS inhibitor therapy in patients with heart failure and chronic kidney disease 6. In your patient with K+ 5.2, addressing any reversible factors (diet, medications, constipation) should occur alongside binder initiation 6. However, if no acute reversible factor exists, treatment to prevent recurrence should be initiated immediately rather than waiting for a second hyperkalemia event 6.